Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

(2022) Kevin L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study

(2022) Yeo-Jin Song et al.   RMD Open

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2021) Liana Fraenkel et al.   Arthritis & Rheumatology

Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study

(2020) Xia Zhao et al.   Clinical Pharmacology in Drug Development

Diagnosis and Management of Rheumatoid Arthritis

(2018) Daniel Aletaha et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Novel treatment strategies in rheumatoid arthritis

(2017) Gerd R Burmester et al.   LANCET

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

(2016) Mohamed-Eslam F. Mohamed et al.   CLINICAL PHARMACOKINETICS

Operational Characteristics of Linear Concentration-QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies

(2016) C Garnett et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rheumatoid arthritis

(2016) Josef S Smolen et al.   LANCET

Which QT Correction Formulae to Use for QT Monitoring?

(2016) Bert Vandenberk et al.   Journal of the American Heart Association

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

(2014) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Systematic Evaluation of Dose Accumulation Studies in Clinical Pharmacokinetics

(2013) Lujin Li et al.   CURRENT DRUG METABOLISM

Back to the future: oral targeted therapy for RA and other autoimmune diseases

(2013) John J. O'Shea et al.   Nature Reviews Rheumatology